Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO‐1701. Issue 5 (24th March 2020)

• Record Type: Journal Article
• Authors: Nishisaka, Fukiko; Taniguchi, Keisuke; Tsugane, Momomi; Hirata, Genya; Takagi, Akimitsu; Asakawa, Naoyuki; Kurita, Akinobu; Takahashi, Hiroyuki; Ogo, Naohisa; Shishido, Yoshiyuki; Asai, Akira
• Is Part Of: Cancer science. Volume 111:Issue 5(2020)
• Page Start: 1774
• Page End: 1784
• Publication Date: 2020-03-24
• Subjects: combination therapy -- SH2 domain -- signaling pathway -- sorafenib -- STAT3 inhibitor; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.14369
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: The signal transducer and activator of transcription 3 (STAT3) signaling pathway is a key mediator of cancer cell proliferation, survival and invasion. Aberrant STAT3 has been demonstrated in various malignant cancers. YHO‐1701 is a novel quinolinecarboxamide derivative generated from STX‐0119. Here, we examined the effect of YHO‐1701 on STAT3 and evaluated antitumor activity of YHO‐1701 as a single agent and in combination. YHO‐1701 inhibited STAT3‐SH2 binding to phospho‐Tyr peptide selectively and more potently than STX‐0119 in biochemical assays. Molecular docking studies with STAT3 suggested more stable interaction of YHO‐1701 with the SH2 domain. YHO‐1701 exhibited approximately 10‐fold stronger activity than STX‐0119 in abrogating the STAT3 signaling pathway of human oral cancer cell line SAS. YHO‐1701 also blocked multi‐step events by inhibiting STAT3 dimerization and suppressed STAT3 promoter activity. As expected, YHO‐1701 exerted strong antiproliferative activity against human cancer cell lines addicted to STAT3 signaling. Orally administered YHO‐1701 showed statistically significant antitumor effects with long exposure to high levels of YHO‐1701 at tumor sites in SAS xenograft models. Moreover, combination regimen with sorafenib led to significantly stronger antitumor activity. In addition, the suppression level of survivin (a downstream target) was superior for the combination as compared with monotherapy groups within tumor tissues. Thus, YHO‐1701 had a favorable specificity for STAT3 and pharmacokinetics after oral treatment; it also contributed to the enhanced antitumor activity of sorafenib. The evidence presented here provides justification using for this approach in future clinical settings. Abstract : YHO‐1701 is a novel small molecule STAT3 inhibitor with quinolinecarboxamide scaffold, which was designed to antagonize SH2‐dependent dimerization of STAT3. This compound inhibited proliferation of human cancer cell lines addicted to STAT3 signaling. YHO‐1701 showed a preferable PK profile with good oral bioavailability in mice and exhibited significant antitumor activity, especially in combination with a multi‐kinase inhibitor sorafenib in a SAS xenograft model.